Time is precious and so is your patient’s tumor sample. Make the most of both with the Oncotype MAP Pan-Cancer Tissue test.
Results in 3-5 business days*† from samples as small as 3mm2 of tissue‡, about the size of a grain of rice.
Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) “strongly advises broader molecular profiling with the goal of identifying rarer driver mutations for which effective drugs may already be available, or to appropriately counsel patients regarding the availability of clinical trials. Broad molecular profiling is a key component of the improved care of patients with NSCLC.”1
Explore the benefits of the Oncotype MAP Pan-Cancer Tissue Test
Why use a large panel? Benefits of comprehensive genomic testing
Testing a single gene at a time or utilizing a small biomarker panel can exhaust available tissue before you find the answer you need. A recent study found >60% of patients with NSCLC have an actionable mutation when a multigene testing panel is used compared to 25% (or less) when single gene testing is used.2
The Oncotype MAP Pan-Cancer Tissue test delivers comprehensive, personalized guidance and clinical trial-driven treatment recommendations in advanced cancer patients for fast results using a small amount of tissue. Worried that your sample size is too small? The Oncotype MAP test will provide quantity not sufficient (QNS) results in as few as 2 business days*†
so you can make quick decisions for your patient.
Stay current with biomarker based therapeutic options
The continuous evolution in the precision oncology landscape for NSCLC has meant frequent updates to recommendations for biomarker testing and changes to the NCCN Guidelines®. The Oncotype MAP Pan-Cancer Tissue test identifies genomic alterations with both NGS and IHC signatures to help stay current with therapeutic options best suited to your patients per the NCCN’s latest recommendations in biomarker testing in record time.